These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis. Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256 [TBL] [Abstract][Full Text] [Related]
8. IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients. Liu Y; Qin G; Meng Z; Du T; Wang X; Tang Y; Cao J Inflammopharmacology; 2019 Feb; 27(1):57-66. PubMed ID: 30242748 [TBL] [Abstract][Full Text] [Related]
9. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. Kircik L; Bagel J; Korman N; Menter A; Elmets CA; Koo J; Yang YC; Chiou CF; Dann F; Stevens SR; J Drugs Dermatol; 2008 Mar; 7(3):245-53. PubMed ID: 18380206 [TBL] [Abstract][Full Text] [Related]
10. Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis. Bae SH; Yun SJ; Lee JB; Kim SJ; Won YH; Lee SC J Dermatol; 2016 Jun; 43(6):643-9. PubMed ID: 26598783 [TBL] [Abstract][Full Text] [Related]
11. [Ramadan and bipolar disorder: Example of circadian rhythm disturbance and its impact on patients with bipolar disorders]. Eddahby S; Kadri N; Moussaoui D Encephale; 2013 Sep; 39(4):306-12. PubMed ID: 23545475 [TBL] [Abstract][Full Text] [Related]
12. Calcipotriol/betamethasone ointment compared to narrow-band UVB in plaque psoriasis: first clinical and ultrasonographic study. Polańska A; Gaura T; Bowszyc-Dmochowska M; Osmola-Mańkowska A; Olek-Hrab K; Adamski Z; Żaba R; Dańczak-Pazdrowska A Int J Dermatol; 2019 Jan; 58(1):108-113. PubMed ID: 30070356 [TBL] [Abstract][Full Text] [Related]
13. Ramadan fasting in Saudi Arabia is associated with altered expression of CLOCK, DUSP and IL-1alpha genes, as well as changes in cardiometabolic risk factors. Ajabnoor GM; Bahijri S; Shaik NA; Borai A; Alamoudi AA; Al-Aama JY; Chrousos GP PLoS One; 2017; 12(4):e0174342. PubMed ID: 28384165 [TBL] [Abstract][Full Text] [Related]
14. The effect of Ramadan fasting on quiescent systemic lupus erythematosus (SLE) patients' disease activity, health quality of life and lipid profile: a pilot study. Goharifar H; Faezi ST; Paragomi P; Montazeri A; Banihashemi AT; Akhlaghkhah M; Abdollahi BS; Kamazani Z; Akbarian M Rheumatol Int; 2015 Aug; 35(8):1409-14. PubMed ID: 25972126 [TBL] [Abstract][Full Text] [Related]
15. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. Gottlieb AB; Matheson RT; Menter A; Leonardi CL; Day RM; Hu C; Schafer PH; Krueger JG J Drugs Dermatol; 2013 Aug; 12(8):888-97. PubMed ID: 23986162 [TBL] [Abstract][Full Text] [Related]
16. Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis. Calzavara-Pinton PG; Sala R; Arisi M; Rossi MT; Venturini M; Ortel B Br J Dermatol; 2013 Jul; 169(1):130-6. PubMed ID: 23834117 [TBL] [Abstract][Full Text] [Related]
17. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944 [TBL] [Abstract][Full Text] [Related]
18. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016 [TBL] [Abstract][Full Text] [Related]
19. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study. Coimbra S; Oliveira H; Reis F; Belo L; Rocha S; Quintanilha A; Figueiredo A; Teixeira F; Castro E; Rocha-Pereira P; Santos-Silva A Am J Clin Dermatol; 2010 Dec; 11(6):423-32. PubMed ID: 20429617 [TBL] [Abstract][Full Text] [Related]
20. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients. Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]